Inhibition of BIRC5 and MCL-1 as potential treatment strategy to overcome drug resistance in Mantle Cell Lymphoma
Pfitzer, J.; Chakravarti, S.; Mazumder, S.; Mukherjee, U. K.; Mitra, A. K.
Show abstract
Mantle cell lymphoma (MCL) is a difficult-to-cure, highly heterogeneous, and aggressive form of non-Hodgkin lymphoma with a high recurrence rate and poor long-term prognosis. Using a novel optimization-regularization-based computational prediction algorithm called "secDrug," we have identified therapeutic targets for treating resistant cancers. When applied to B-cell malignancies, the secDrug algorithm predicted the pro-survival proteins BIRC5 and MCL1 as top targets. Here, using a panel of MCL cell lines representing PI/BTKi sensitive, innate resistance, and clonally derived acquired resistance, we demonstrated that small molecule-based inhibition of BIRC5 and MCL1 is effective in killing MCL cells as single agents and in combination with Bortezomib or Ibrutinib. Further, using bulk and single-cell transcriptomics, gene knockdown studies, and cell-based assays, we identified genes and molecular networks associated with their mechanism of action and synergy. In silico analysis using patient datasets underlined the clinical potential of these candidates in curbing MCL progression and drug resistance.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Development of a Novel Bruton's Tyrosine Kinase Inhibitor that exerts Anti-Cancer Activities Potentiates Response of Chemotherapeutic Agents In Multiple Myeloma Stem Cell-Like Cells 97%
- The mitochondrial deubiquitinase USP30 regulates AKT/mTOR signaling 95%
- Antitumor Activities and Cellular Changes Induced by TrkB Inhibition in Medulloblastoma 93%
Similar papers in this journal
Similar papers in this journal
- A novel triple-action inhibitor targeting B-cell receptor signaling and BRD4 demonstrates preclinical activity in chronic lymphocytic leukemia 94%
- Multiscale Analysis And Validation Of Effective Drug Combinations Targeting Driver Kras Mutations In Non-Small Cell Lung Cancer 92%
- Small-molecule inhibitors of the RNA m6A demethylase FTO potently support the survival of dopamine neurons 92%
Similar papers in this journal
- A novel anti-PD-L1/IL-15 immunocytokine overcomes resistance to PD-L1 blockade and elicits potent antitumor immunity 93%
- Non-canonical role of Hippo tumor suppressor serine/threonine kinase 3 STK3 in prostate cancer 92%
- Balancing activation and costimulation of CAR tunes signaling dynamics and enhances therapeutic potency 92%
Similar papers in this journal
- A subset of CB002 xanthine analogues bypass p53-signaling to restore a p53 transcriptome and target an S-phase cell cycle checkpoint in tumors with mutated-p53 95%
- Discovery and biological evaluation of a potent small molecule CRM1 inhibitor for its selective ablation of extranodal NK/T cell lymphoma 95%
- NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.